Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × talazoparib × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 6 Genitourinary 5 Gynecologic 3 Gastrointestinal 3 Sarcoma 2 Other hematologic neoplasm 2 Tumor-Agnostic 1 Thoracic 1 Plasma cell 1 NET 1 Myeloid 1 Lymphoid 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 14 Magnetic Resonance Spectroscopy 8 Everolimus 8 gallium Ga 68 dotatate 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 lanreotide 4 Specimen Handling 4 olaparib 3 cabozantinib 3 Somatostatin 3 Nivolumab 3 Lutetium-177 3 Injections 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 Capecitabine 3 surufatinib 2 pembrolizumab 2 fludarabine phosphate 2 fludarabine 2 copper dotatate CU-64 2 amino-acid, glucose, and electrolyte solution 2 Temozolomide 2 Sunitinib 2 Octreotide 2 Lutetium 2 Ga(III)-DOTATOC 2 Drug Therapy 2 64Cu-DOTATATE 2 zimberelimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡